What changed from existing technology?
This study looked at how well a test called Oncotype Dx can predict the outcome for patients with a rare type of breast cancer that has low levels of estrogen receptors.
This is the first study to evaluate the prognostic value of Oncotype Dx specifically in ER-low-positive breast cancer patients, a subtype that has not been previously studied in this context.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
Assessing the prognostic utility of Oncotype Dx among patients with ER-low-positive breast cancer in the National Cancer Database (NCDB). Oncotype Dx (ODX) h
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Oncotype Dx may be useful for predicting outcomes in ER-low-positive, node-negative breast cancer patients, potentially guiding treatment decisions.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.